Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Data from the SUNRISE-FA study showed that treatment with LX2006 achieved a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline. LVMI is an estimator of cardiac morbidity and mortality. Treatment with the therapy was also well-tolerated across all study participants, with no treatment-related serious adverse events. Shares of Lexeo Therapeutics (LXEO) lost 26% on Monday after it reported positive interim data from t ...